The role of hormonal factors and endocrine therapy in ovarian cancer

Wspolczesna Onkologia

Volumn 17, Issue 1, 2013, Pages 14-19

  Serkies, Krystyna ^a   Sinacki, Marcin ^a   Jassem, Jacek ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Aromatase inhibitors; Endocrine therapy; Estrogens; Ovarian cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CISPLATIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIPTORELIN;

ADVANCED CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CARCINOGENESIS; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TUMOR REGRESSION;

EID: 84876207386     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.33768     Document Type: Review

References (51)

1. Didkowska J, Wojciechowska U, Tarnowski W, Zatoński W. Nowotwory złośliwe w Polsce w 2009 roku. Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warszawa 2011.
2. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
3. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
4. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.
5. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-707.
6. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-8.
7. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: Is there a role? Int J Gynecol Cancer 2008; 18: 600-14.
8. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007; 17: 325-38.
9. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: A meta-analysis. Gynecol Oncol 2008; 108: 641-51.
10. Kommoss F, Pfisterer J, Thome M, Schäfer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47: 317-22.
11. Zhou R, Treeck O, Horn F, Ortmann O. Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells. Gynecol Oncol 2005; 96: 678-83.
12. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor{beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193: 421-33.
13. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009; 114: 480-5.
14. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000; 27: 75-93.
15. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000; 21: 40-54.
16. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 2007; 106: 461-8.
17. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4 and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 2007; 13: 1438-44.
18. Swerdlow AJ, Jones ME. Ovarian cancer risk in premenopausal and perimenopausal women treated with tamoxifen: A case-control study. Br J Cancer 2007; 96: 850-5.
19. Wright JW, Stouffer RL, Rodland KD. High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. J Clin Endocrinol Metab 2005; 90: 3688-95.
20. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research. Gynecol Oncol 2002; 84: 201-9.
21. Schwartz PE, Chambers JT, Kohorn EI, Chambers SK, Weitzman H, Voynick IM, MacLusky N, Naftolin F. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer 1989; 63: 1074-8.
22. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957-68.
23. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269-71.
24. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, Aydiner A, Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007; 24: 39-43.
25. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996; 62: 4-6.
26. Sirisabya N, Li Y, Jaishuen A, Zheng HG, Gershenson DM, Kavanagh JJ. Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2008; 18: 648-51.
27. Benedetti Panici P, Greggi S, Amoroso M, et al. A combination of platinum and tamoxifen in advanced ovarian cancer failling platinumbased chemotherapy: Results of a phase II study. Int J Gynecol Cancer 2001; 11: 438-44.
28. Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol 2009; 113: 205-9.
29. Perry WL 3rd, Shepard RL, Sampath J, et al. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drug when overexpressed-a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res 2005; 65: 6593-600.
30. Kühnel R, Delemarre JF, Rao BR, Stolk JG. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res 1986; 6: 889-92.
31. Noguchi T, Kitawaki J, Tamura T, Kim T, Kanno H, Yamamoto T, Okada H. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 1993; 44: 657-60.
32. Cunat S, Rabenoelina F, Daurčs JP, Katsaros D, Sasano H, Miller WR, Maudelonde T, Pujol P. Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 2005; 93: 15-24.
33. Kitawaki J, Noguchi T, Yamamoto T, Yokota K, Maeda K, Urabe M, Honjo H. Immunohistochemical localization of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Anticancer Res 1996; 16: 91-97.
34. Slotman BJ, Kühnel R, Rao BR, Dijkhuizen GH, de Graaff J, Stolk JG. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989; 33: 76-81.
35. Langdon SP, Smyth JF. Hormone therapy for epithelial ovarian cancer. Curr Opin Oncol 2008; 20: 548-53.
36. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004; 66: 112-7.
37. Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am J Surg 2005; 190: 570-1.
38. Chen D, Hackl W, Ortmann O, Treeck O. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs 2004; 15: 55-61.
39. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF. Ca125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002; 8: 2233-9.
40. Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13: 3617-22.
41. Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum-and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 2008; 110: 56-9.
42. Rzepka-Górska I, Chudecka-Glaz A, Kosmider M, Malecha J. GnRH analogues as an adjuvant therapy for ovarian cancer patients. Int J Gynaecol Obstet 2003; 81: 199-205.
43. Sevelda P, Vavra N, Fitz R, Barrada M, Salzer H, Baur M, Dittrich C. Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer 1992; 2: 160-162.
44. Duffaud F, van der Burg ME, Namer M, et al. D-TRP-6 LHRH (Triptorelin) is not effective in ovarian carcinoma: An EORTC study. Anticancer Drugs 2001; 12: 159-62.
45. Emons G, Ortmann O, Teichert HM, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996; 78: 1452-60.
46. duBois A, Meier W, Lück HJ, et al. Chemotherapy versus hormonal treatment in platinum-and paclitaxel-refractory ovarian cancer: A randomized trial of the Germans Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002; 13: 251-7.
47. Paskeviciute L, Roed H, Engelholm S. No rules without exception: Long term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 2002; 86: 297-301.
48. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005; 93: 647-51.
49. Hofstra LS, Mourits MJ, de Vries EG, Mulder NH, Willemse PH. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res 1999; 19: 3627-30.
50. Levine D, Park K, Juretzka M, et al. A phase II evaluation of goserelin and bicalutamide with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007; 110: 2448-56.
51. National Comprehensive Cancer Network (NCCN) v. 3. 2012.